MeiraGTx Holdings plc (MGTX)
NASDAQ: MGTX · Real-Time Price · USD
9.08
-0.05 (-0.55%)
At close: Apr 28, 2026, 4:00 PM EDT
9.08
0.00 (0.00%)
After-hours: Apr 28, 2026, 6:03 PM EDT
MeiraGTx Holdings Employees
As of December 31, 2025, MeiraGTx Holdings had 403 total employees, including 400 full-time and 3 part-time employees. The number of employees increased by 22 or 5.77% compared to the previous year.
Employees
403
Change (1Y)
22
Growth (1Y)
5.77%
Revenue / Employee
$201,963
Profits / Employee
-$283,377
Market Cap
840.42M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| MannKind | 592 |
| Phathom Pharmaceuticals | 371 |
| ARS Pharmaceuticals | 163 |
| Theravance Biopharma | 90 |
| CytomX Therapeutics | 69 |
| Alto Neuroscience | 68 |
| Crescent Biopharma | 44 |
| Bright Minds Biosciences | 26 |
MGTX News
- 12 days ago - Eli Lilly Partner MeiraGTx Regains Rights For Genetic Eye Disease Drug From Johnson & Johnson - Benzinga
- 12 days ago - MeiraGTx Holdings Transcript: KOL event - Transcripts
- 12 days ago - MeiraGTx Announces Pricing of $100 Million Offering of Ordinary Shares - GlobeNewsWire
- 12 days ago - MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP) - GlobeNewsWire
- 12 days ago - MeiraGTx Announces Positive Three-year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Late Radiation-Induced Xerostomia - GlobeNewsWire
- 14 days ago - MeiraGTx to Present 3-Year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Thursday, April 16, 2026 - GlobeNewsWire
- 4 weeks ago - MeiraGTx Announces FDA Breakthrough Therapy Designation for AAV2-hAQP1 for the Treatment of Grade 2 and Grade 3 Radiation-Induced Xerostomia (RIX) and Reports Fourth Quarter and Full Year 2025 Financial and Operational Results - GlobeNewsWire
- 4 weeks ago - MeiraGTx Holdings Transcript: RBC Capital Markets Virtual Ophthalmology Conference - Transcripts